Heredia

Researchers are conducting an observational study to evaluate the quality of care for patients with soft-tissue sarcoma, gastrointestinal stromal tumor GIST, and bone sarcoma. The study compares outcomes such as relapse-free survival, overall survival, and amputation rates between expert and non-expert centers. Expert pathology peer reviews and translational research on tumor samples from four sarcoma subtypes are included to explore biomarkers and develop preclinical models. The study includes both retrospective data from January 2012 to June 2019 and prospective data from July 2019 to January 2022. Data collected involves clinical and treatment information registered in a shared database. Quality indicators assessed include biopsy methods, imaging studies, multidisciplinary team discussions, surgical margins, re-resections, radiotherapy use, and molecular status assessments for GIST. Tumor samples will be analyzed by expert centers for diagnosis differences and biomarker research. Participants will provide informed consent and clinical data will be collected and analyzed over approximately three years. The study measures various quality and outcome indicators such as biopsy rates, imaging, surgical margins, survival rates, and amputation frequencies. Tumor tissue samples will be used for genetic and protein analyses, with some fresh samples used to create models for further research. Patients may withdraw consent at any time without affecting their care or participation in data collection.